THAR_OUT_1 [2025-04-29 04:22:02 -0400] 5976 Bytes | 1556 tokens | Cum: 1556 tkns (19.45% of 8k)
==========================================================================

By the grace of fortune and the swing of fate, Tharimmune (THAR) hath moved from $1.36 to $1.40. 'Tis 4:22 AM on Tue Apr 29, 2025. We must needs inquire—doth this path lead unto riches or ruin?

--- COMPANY PROFILE ---
Company: Tharimmune (THAR)
IPO: 2022-01-12 (3 Years Ago)
Market Cap: $2,425,066
Shares Outstanding: 2,110,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.

Here’s a list of headlines for Tharimmune:

Apr-28-25 08:01AM - Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback
Apr-15-25 09:00AM - Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors
Apr-07-25 08:00AM - Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology
Mar-31-25 08:00AM - Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure
Mar-04-25 07:00AM - Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology
Jan-27-25 08:30AM - Tharimmune to Present at the Microcap Conference 2025
Dec-16-24 08:00AM - Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update
Dec-06-24 04:15PM - Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs
Nov-27-24 07:00AM - DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025
Nov-18-24 08:00AM - Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease
Nov-13-24 08:00AM - Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics
Nov-04-24 09:00AM - Tharimmune Announces Upcoming Conference Presentations
Oct-30-24 08:00AM - Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis
Oct-28-24 09:00AM - Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting
Oct-25-24 08:00AM - Tharimmune Announces Upcoming Conference Presentations
Sep-30-24 07:00AM - Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company
Sep-16-24 07:00AM - Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab
Jul-22-24 08:30AM - Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board
Jul-17-24 08:30AM - Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor
Jul-16-24 08:30AM - Tharimmune Launches New Website as Discussions with FDA Continue for Phase 2 Clinical Trial with TH104
Jun-10-24 08:00AM - Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
May-29-24 08:30AM - Tharimmune to Present at 2024 BIO International Convention

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2023-12-19T13:29:10Z - Perspective Therapeutics And 3 Other Stocks Under $1 Insiders Are Buying
B2 - 2023-12-08T13:05:42Z - Why Hello Group Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
B3 - 2023-11-28T19:57:31Z - Crude Oil Surges 2%; Tharimmune Shares Plummet
B4 - 2023-11-28T19:44:53Z - Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
B5 - 2023-11-28T17:24:00Z - Tharimmune (THAR) Up on Positive Data From Pipeline Candidate
B6 - 2023-11-28T14:33:13Z - US Stocks Mixed; House Prices Rise In September

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Tharimmune (THAR).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

THAR_OUT_3 [2025-04-29 04:22:02 -0400] 1187 Bytes | 346 tokens | Cum: 1904 tkns (23.80% of 8k)
==========================================================================

Showing B3 (chunk 1 of 2): B3:
**Crude Oil Surges 2%; Tharimmune Shares Plummet**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/news/earnings/23/11/35987910/crude-oil-surges-2-tharimmune-shares-plummetU.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 100 points on Tuesday.
The Dow traded up 0.27% to 35,429.20 while the NASDAQ rose 0.12% to 14,258.32. The S&P 500 also rose, gaining, 0.07% to 4,553.52.
Check This Out: How To Make $500 A Month With Microsoft As The Stock Hits An All-Time High
 
Leading and Lagging Sectors
 
Consumer discretionary shares rose by 0.5% on Tuesday.
In trading on Tuesday, health care shares fell by 0.4%.
 
Top Headline
 
The Dallas Fed general business activity index for Texas' service sector rose to -11.6 in November compared to a 10-month low level of -18.2 in October.
 
Equities Trading UP
 
Carbon Revolution Public Lim

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

THAR_OUT_5 [2025-04-29 04:22:03 -0400] 713 Bytes | 197 tokens | Cum: 2103 tkns (26.29% of 8k)
==========================================================================

Showing B3 (chunk 2 of 2): ited Company (NASDAQ: CREV) shares shot up 30% to $33.55 after Craig-Hallum initiated coverage on the stock with a Buy rating and a $84 price target.
Shares of PDD Holdings Inc. (NASDAQ: PDD) got a boost, shooting 18% to $138.70 after the company reported third-quarter financial results.
IceCure Medical Ltd (NASDAQ: ICCM) shares were also up, gaining 81% to $1.3628 after the company announced the latest release of a study ...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

THAR_OUT_7 [2025-04-29 04:22:03 -0400] 1014 Bytes | 303 tokens | Cum: 2408 tkns (30.10% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-28T14:01:00Z - Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids...
A2 - 2025-04-28T12:12:57Z - 12 Health Care Stocks Moving In Monday's Pre-Market Session - Autonomix Medical (NASDAQ:AMIX), Abpro...
A3 - 2025-04-28T12:06:17Z - Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids...
A4 - 2025-04-28T12:20:11Z - FDA Nods to Tharimmune's Countermeasure for Opioid Threats By Investing.com...
A5 - 2025-04-28T12:13:20Z - Tharimmune (THAR) Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency ...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

THAR_OUT_9 [2025-04-29 04:22:04 -0400] 1181 Bytes | 315 tokens | Cum: 2725 tkns (34.06% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback**Date: 2025-04-28Source: {'uri': 'wallstreet-online.de', 'dataType': 'news', 'title': 'wallstreet:online'}URL: https://www.wallstreet-online.de/nachricht/19277554-tharimmune-advances-th104-for-prophylaxis-against-weaponized-fentanyl-and-other-high-potency-opioids-following-positive-fda-feedbackBRIDGEWATER, NJ / ACCESS Newswire / April 28, 2025 / Tharimmune, Inc., (Nasdaq:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology, recently announced positive feedback from the U.S. Food and Drug Administration (FDA) regarding TH104. The agency confirmed that no additional clinical trials appear to be necessary prior to a 505(b)(2) New Drug Application (NDA)

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

THAR_OUT_11 [2025-04-29 04:22:05 -0400] 1181 Bytes | 246 tokens | Cum: 2973 tkns (37.16% of 8k)
==========================================================================

Showing A1 (chunk 2 of 4): submission. TH104 is a buccal film formulation, of nalmefene specifically designed for rapid absorption with a potential for bypassing liver metabolism. This allows TH104 to be suitable for the temporary prophylaxis of respiratory and/or nervous system depression in military personnel and chemical incident responders who may be exposed to high-potency opioids, including weaponized fentanyl and its analogues.

This significant regulatory milestone underscores the urgent need for specialized medical countermeasures highlighted in a recent market assessment concerning the United States Strategic National Stockpile (SNS). This assessment specifically addressed the growing threat posed by chemicals of concern, with a primary focus on the increasing risk of high-potency synthetic opioids like fentanyl and its numerous derivatives being weaponized and deployed as aerosolized agents.

The U.S. g

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

THAR_OUT_13 [2025-04-29 04:22:05 -0400] 1181 Bytes | 233 tokens | Cum: 3208 tkns (40.10% of 8k)
==========================================================================

Showing A1 (chunk 3 of 4): overnment has increasingly recognized fentanyl and its related compounds as significant national security threats due to their extreme potency and the potential for mass casualty incidents if weaponized. These substances, significantly more potent than traditional opioids, pose a grave risk through inhalation, dermal contact, or ingestion. The 2002 Moscow theater hostage crisis, where aerosolized synthetic opioids were reportedly used, tragically demonstrated the devastating potential of such agents in a mass casualty scenario. This event, alongside intelligence indicating potential adversary interest in opioid-based chemical weapons, has heightened the priority for developing effective prophylactic measures for frontline personnel/first responders.

SNS market assessment identified a critical need for countermeasures that can be administered prior to or immediately upon potential exposu

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

THAR_OUT_15 [2025-04-29 04:22:06 -0400] 476 Bytes | 118 tokens | Cum: 3328 tkns (41.60% of 8k)
==========================================================================

Showing A1 (chunk 4 of 4): re to these agents, preventing or mitigating the rapid onset of respiratory and nervous system depression. Key findings from this analysis further emphasize the importance of Tharimmune's work:

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

THAR_OUT_17 [2025-04-29 04:22:06 -0400] 1074 Bytes | 297 tokens | Cum: 3627 tkns (45.34% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S2 - 2025-03-25 10-K ITEM 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER.

You should read the following discussion and analysis of our financial condition and plan of operations together with and our accompanying CONS financial statements and the re...

S3 - 2024-12-06 8-K Item 1.01 Entry into a Material Definitive Agrmt

On December 5, 2024, Tharimmune, Inc. (the Company) entered into a securities purchase agreement (the Purchase Agrmt) with certain institutional investors (the Purchasers) for the issuance and sale in a private placement ...

S4 - 2024-11-07 10-Q COND CONS BAL SHEETS

September 30, 2024 December 31, (Unaudited) 2023 ASSETS Curr assets Cash and cash equiv $ 4,774,237 $ 10,935,352 Prepaid expenses and other current assets 477,009 11,041 Total current assets 5,251,246 10,946,393 Total assets $ 5,...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

THAR_OUT_19 [2025-04-29 04:22:07 -0400] 1181 Bytes | 249 tokens | Cum: 3878 tkns (48.48% of 8k)
==========================================================================

Showing S2 (chunk 1 of 6): S2:
ITEM 7. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

You should read the following discussion and analysis of our financial condition and plan of operations together with and our accompanying consolidated financial statements and the related notes appearing elsewhere in this Annual Report on Form 10-K. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled Risk Factors included elsewhere in this Annual Report on Form 10-K. All amounts in this report are in U.S. dollars, unless otherwise noted.

Overview

Tharimmune is

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

THAR_OUT_21 [2025-04-29 04:22:08 -0400] 1181 Bytes | 272 tokens | Cum: 4152 tkns (51.90% of 8k)
==========================================================================

Showing S2 (chunk 2 of 6): a clinical-stage biotechnology company developing therapeutic candidates in immunology and inflammation with high unmet need. On November 3, 2023, we entered into a patent license agreement (the Avior License Agreement) with Avior Inc. d/b/a Avior Bio, LLC (Avior) pursuant to which we received an exclusive sublicensable right and license to Licensed Patent Rights and Licensed Technology to, among other things, Develop, have Developed, make, have made, use, sell, import, export and commercialize TH104 and TH103 and to practice the Licensed Technology in connection with the foregoing, throughout the world, each as defined in the Avior License Agreement. In February 2023, the U.S. Food and Drug Administration (FDA) approved an investigational new drug (IND) application for TH104. TH104 has a dual mechanism of action by affecting multiple receptors, known to suppress chronic, debilitating pr

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

THAR_OUT_23 [2025-04-29 04:22:09 -0400] 1181 Bytes | 299 tokens | Cum: 4453 tkns (55.66% of 8k)
==========================================================================

Showing S2 (chunk 3 of 6): uritus or uncontrollable itching. With respect to TH104, we intend to first seek approval for the treatment of moderate-to-severe chronic pruritus in patients with primary biliary cholangitis (PBC), an orphan rare form of liver disease with no known cure in which more than 70% of patients suffer from debilitating chronic pruritic. We expect to obtain topline data from a Phase 2 trial in TH104 in Q4 2025 and with respect to TH103, we intend to develop the product candidate and potentially file an IND.

##TABLE_START 67 ##TABLE_END

On September 11, 2024, we entered into a Patent License Agreement (the Intract Agreement) with Intract Pharma Limited (Intract), pursuant to which, we exclusively licensed INT-023/TH023, an oral anti-Tumor Necrosis Factor-alpha (TNF-) monoclonal antibody infliximab. Infliximab is a purified, recombinant DNA-derived chimeric IgG monoclonal antibody protein that

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

THAR_OUT_25 [2025-04-29 04:22:09 -0400] 1181 Bytes | 271 tokens | Cum: 4726 tkns (59.08% of 8k)
==========================================================================

Showing S2 (chunk 4 of 6): contains both murine and human components that inhibit tumor TNF-. Under the terms of the Intract Agreement, we licensed global development and commercialization rights (outside of South Korea) to Intracts Soteria and Phloral delivery platform along with an existing supply agreement for infliximab to be used in the oral product development program.

We are also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immuno-oncology (IO) targets including human epidermal growth factor (EGF) receptor 2 (HER2), human EGF receptor 3 (HER3) and programmed cell death protein 1 (PD-1). We are developing antibodies including bispecific antibodies, antibody drug conjugates (ADCs) and small molecular weight bovine-derived Picobodies or antibody knob domains which have the potential to target and bind more tightly to undruggable epitopes better than full

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

THAR_OUT_27 [2025-04-29 04:22:10 -0400] 1181 Bytes | 287 tokens | Cum: 5015 tkns (62.69% of 8k)
==========================================================================

Showing S2 (chunk 5 of 6): sized antibodies. We are advancing HS3215, a bispecific against both HER2 and HER3 antibody which targets a novel bridging epitope encompassing multiple domains of the HER2 extracellular domain (ECD) as well as ligand-dependent and independent blocking of the ECD of HER3 into IND-enabling studies in 2025. In addition, we anticipate that HS0059, a HER2/HER3 bispecific ADC (bsADC), and HS1940, a PD-1 Picobody, will progress to enter IND-enabling studies in 2025.

The critical components of our business strategy to achieve our goals include:

##TABLE_START Develop TH104 as a transmucosal buccal film product for the treatment of moderate-to-severe chronic pruritus in PBC and other inflammatory diseases; Develop TH023 by obtaining regulatory authorization to initiate a first-in-human bioavailability clinical trial and pursue an IND through the US FDA; Create a preclinical and clinical path

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

THAR_OUT_29 [2025-04-29 04:22:11 -0400] 790 Bytes | 181 tokens | Cum: 5198 tkns (64.98% of 8k)
==========================================================================

Showing S2 (chunk 6 of 6): forward for, HS1940, a unique PD-1 knob-domain antibody fragment with unique binding differentiation compared to full length antibodies for IO vulnerable tumors; Continue to advance pre-clinical candidate selection activities against HER2/HER3 receptors with various antibody formats, including HS3215 designed for multiple solid tumor types; Effectively create a strategy to develop HS0059 as a bispecific ADC specifically targeted to both HER2 and HER3 receptors in high unmet need standard-of-care res...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

THAR_OUT_31 [2025-04-29 04:22:16 -0400] 5799 Bytes | 1556 tokens | Cum: 6756 tkns (84.45% of 8k)
==========================================================================

This is our set of metrics for Tharimmune.
Please analyze the numbers.

+---------------------+-----------------------+------------------------+-------------------+
| Volume: 1,920,825 | Perf Month: 0.00% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+------------------------+-------------------+
| Avg Volume: 109.59K | Perf Quarter: -32.34% | Short Float: 3.55% | ROE: -233.69% |
+---------------------+-----------------------+------------------------+-------------------+
| Rel Volume: 24.23 | Index: - | Short Ratio: 0.67 | ROI: -932.79% |
+---------------------+-----------------------+------------------------+-------------------+
| RSI (14): 57.71 | Market Cap: 2.87M | Short Interest: 0.07M | Sales Surprise: - |
+---------------------+-----------------------+------------------------+-------------------+
| ATR (14): 0.13 | Shs Outstand: 2.11M | Beta: 1.17 | EPS Surprise: - |
+---------------------+-----------------------+------------------------+-------------------+
| SMA20: 14.72% | Shs Float: 2.07M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+------------------------+-------------------+
| SMA50: -2.95% | Inst Own: 7.07% | Sales past 5Y: 0.00% | Earnings: Feb 26 |
+---------------------+-----------------------+------------------------+-------------------+
| SMA200: -39.11% | Insider Own: 1.62% | Employees: 2 | |
+---------------------+-----------------------+------------------------+-------------------+
| Perf Week: 18.26% | Insider Trans: 39.05% | Debt/Eq: 0.00 | |
+---------------------+-----------------------+------------------------+-------------------+

The next section covers any insider trading by Tharimmune officers or majority shareholders (if available).

No transactions recorded.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -12197568.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.36
Average Volume: 192823.5
30-Day High: 1.36
30-Day Low: 1.050503

[Detailed Financials: TTM 2024]
- Total Assets: $3,721,624.00
- Total Liabilities: $2,413,982.00
- Total Equity: $1,307,642.00
- Current Assets: $3,721,624.00
- Current Liabilities: $2,413,982.00

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: $-12,197,568.00
- Gross Profit: N/A
- Operating Income: $-12,433,792.00
- Earnings Per Share (EPS): -9.41

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $0.00

[Detailed Financials: FY 2024]
- Total Assets: $3,721,624.00
- Total Liabilities: $2,413,982.00
- Total Equity: $1,307,642.00
- Current Assets: $3,721,624.00
- Current Liabilities: $2,413,982.00

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: $-12,197,568.00
- Gross Profit: N/A
- Operating Income: $-12,433,792.00
- Earnings Per Share (EPS): -9.41

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $0.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Tharimmune (THAR).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Tharimmune.

2) MARKET_SCORE[]
This conversation was initiated because THAR is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for THAR.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, THAR could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect THAR to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Tharimmune.

11) ETHICAL_RATING[]
Rate Tharimmune’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Tharimmune.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

THAR_IN_33 [2025-04-29 04:22:17 -0400] 126 Bytes | 29 tokens | Cum: 6961 tkns (87.01% of 8k)
==========================================================================

====================================
[2025-04-29 04:22:17] # Analysis Completed
Elapsed Time: 15.82 seconds